MannKind Corporation (MNKD) Stock Ratings


View Stock Quote:

MNKD

Login Required

You must login before you can rate this stock.

Login Now

Community Rating:


Bullish

83% of 6 ratings

View All-Time Ratings

Do the wall street analysts agree?

Consensus Recommendation:

View detailed analyst research

Other Member Ratings

View Most Rated Stocks
Member Call Date Rated Timeframe Start Price End Price Stock Gain/Loss Score Status
TimKlocke 04/11/2013 1 Year $4.26 $5.31 +24.64% 24 Active
Comments: Big money about to be made in one year!!!!
JasonK 04/04/2013 1 Year $3.73 $5.31 +42.4% 42 Active
Comments: If FDA approves Afreeza (sp) this stock will perform well
SupaMario 04/03/2013 3 months $3.79 $5.31 +40.11% -40 Active
Comments: too fast too high. a backdrop is possible
katie t 03/20/2013 3 months $3.38 $5.31 +57.1% 57 Active
Comments:
itssofluffyimgonnadie 02/23/2013 3 months $2.54 $5.31 +109.06% 109 Active
Comments: Afrezza could serve a multi billion dollar market
charliex 02/14/2013 1 Year $2.50 $5.31 +112.4% 112 Active
Comments: Massive upside potential. Afrezza should make it this time.
prometheusX 02/14/2013 3 months $2.46 $4.73 +92.28% 92 Ended
Comments: target price: 4,20 - because they have 2 phase 3-trials and a blockbuster if fda approves in august
JOKER66 10/18/2012 1 day $2.60 $1.99 -23.46% 23 Ended
Comments:
peter_16 01/14/2011 3 months $9.74 $2.68 -72.52% -72 Ended
Comments: Upcoming product launch will be successful
Scott_40 01/11/2011 3 months $8.71 $2.68 -69.29% 69 Ended
Comments: Industry sector declining or poised for decline
carl_15 01/02/2011 3 months $8.06 $2.68 -66.81% -66 Ended
Comments: Upcoming product launch will be successful
WhyMe12 12/12/2010 3 months $7.51 $2.68 -64.38% -64 Ended
Comments: Approval in late Dec or early Jan sends price to low to mid 20s

Neither The NASDAQ OMX Group, Inc. nor any of its affiliates (collectively "NASDAQ OMX") makes any recommendation to buy or sell any security or any representation about the financial condition of any company. Investment related advice and comments are solely those of the individuals who publish them and do not in any way represent the opinions of NASDAQ OMX. Investors should undertake their own due diligence and carefully evaluate companies before investing.